Zealand Pharma (ZEAL.CO) Announces Advance By Sanofi (France) (SAN.PA) Of Lixilan, The Single Injection Lyxumia®/Lantus® Combination Product, Towards Phase 3 Development And A Related Milestone Payment
1/15/2014 2:16:54 PM
Copenhagen, 15 January 2014 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) announces that under its license agreement with Sanofi (EURONEXT: SAN and NYSE: SNY) covering Lyxumia® (lixisenatide) and any combination product including lixisenatide, a milestone has been achieved in the advance of LixiLan, the once-daily single injection Lantus® (basal insulin) / Lyxumia® (lixisenatide) combination product, towards start of Phase III development in the 1st quarter of 2014. The milestone relates to the approval of the first Phase III study protocol for LixiLan by a Health Authority, triggering a USD 15 million payment to Zealand.
Help employers find you! Check out all the jobs and post your resume.
comments powered by